AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6689152 — intervention group
Group type: COMPARATOR
Intervention: Two prolonged acting (PA) Pro‐Banthine 30 mg tablets
Number of subjects: 6
Study 30841858 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg daily for six weeks
Number of subjects: 230
Study 30841858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 29559724 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised dietary advice (I)
Number of subjects: 211
Study 29559724 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised dietary advice supplemented with 30 g walnuts/day (IW)
Number of subjects: 211
Study 29559724 — intervention group
Group type: COMPARATOR
Intervention: General dietary advice (Control)
Number of subjects: 211
Study 27998295 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
Number of subjects: 120
Study 27998295 — intervention group
Group type: COMPARATOR
Intervention: Usual Care followed by Delayed Treatment with TranS-C (UC-DT)
Number of subjects: 120
Study 24381122 — intervention group
Group type: EXPERIMENTAL
Intervention: Prohormone (330 mg/day of 3β‐hydroxy‐5α‐androst‐1‐en‐17‐one)
Number of subjects: 17
Study 24381122 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sugar)
Number of subjects: 17
Study 22620717 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol (POL) 0.5% for telangiectasias
Number of subjects: 63
Study 22620717 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol (POL) 1% for reticular veins
Number of subjects: 63
Study 22620717 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline (HS) 11.7% for telangiectasias
Number of subjects: 63
Study 22620717 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline (HS) 23.4% for reticular veins
Number of subjects: 63
Study 20107727 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Number of subjects: 347
Study 20107727 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus cream
Number of subjects: 347
Study 17327248 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG technique
Number of subjects: 2200
Study 17327248 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG technique
Number of subjects: 2200
Study 15630027 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement CMR in cardiac amyloidosis patients
Number of subjects: 30
Study 14589725 — intervention group
Group type: EXPERIMENTAL
Intervention: Malingering conditions (malingerers, malingerers-with-warning)
Number of subjects: 60
Study 14589725 — intervention group
Group type: COMPARATOR
Intervention: Nonmalingering conditions (warning-only, control)
Number of subjects: 60
Study 10210048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (S group, n = 15) at a minimal concentration of 4% in oxygen for induction and at 0.5‐2 MAC end‐tidal concentration for maintenance.
Number of subjects: 30
Study 10210048 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous technique (T group, n = 15) consisting of midazolam for induction and propofol for maintenance.
Number of subjects: 30
Study 10210048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/sufentanil maintenance
Number of subjects: 30
Study 10210048 — intervention group
Group type: COMPARATOR
Intervention: Propofol/sufentanil technique
Number of subjects: 30
Study 7882465 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 21
Study 7882465 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 21
Study 7882465 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 21
Study 7882465 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 21
Study 3101812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet B phototherapy combined with dithranol using fluorescent lamps with negligible ultraviolet C emission (Wolff Helarium)
Number of subjects: 24
Study 3101812 — intervention group
Group type: COMPARATOR
Intervention: Medium pressure mercury arc lamp
Number of subjects: 24
Study 3101812 — intervention group
Group type: COMPARATOR
Intervention: Array of fluorescent sunlamps
Number of subjects: 24
Study 3101812 — intervention group
Group type: COMPARATOR
Intervention: Dithranol alone
Number of subjects: 24
Study 29265834 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 188
Study 29265834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 188
Study 29265834 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT for insomnia
Number of subjects: 188
Study 28028369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon α-2a (0.5 mg daily for 48 weeks)
Number of subjects: 88
Study 28028369 — intervention group
Group type: COMPARATOR
Intervention: Entecavir (0.5 mg daily for 48 weeks)
Number of subjects: 88
Study 28028369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon α-2a
Number of subjects: 88
Study 25011430 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport participation intervention in three regions of a Rotterdam youth care organization
Number of subjects: 2
Study 25011430 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual in two control regions
Number of subjects: 2
Study 22373031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentis Mplus MIOL
Number of subjects: 80
Study 22373031 — intervention group
Group type: EXPERIMENTAL
Intervention: Acri.Lisa 366 MIOL
Number of subjects: 80
Study 22373031 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL (AR-40e) control group
Number of subjects: 80
Study 22373031 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of zonal refractive and diffractive aspheric MIOLs
Number of subjects: 80
Study 20875522 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration frequency of 26Hz
Number of subjects: 10
Study 20875522 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration frequency of 40Hz
Number of subjects: 10
Study 20875522 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 10
Study 18622271 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcomes research
Number of subjects: 0
Study 18622271 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study 19930883 — intervention group
Group type: EXPERIMENTAL
Intervention: UTI 8 kU/kg (group U1)
Number of subjects: 42
Study 19930883 — intervention group
Group type: EXPERIMENTAL
Intervention: UTI 12 kU/kg (group U2)
Number of subjects: 42
Study 19930883 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 15860850 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 201
Study 11315837 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg daily orally)
Number of subjects: 7
Study 11315837 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (continuous subcutaneous infusion of 2.4 pmol x kg(‐1) x min(‐1))
Number of subjects: 7
Study 11315837 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (metformin + GLP-1)
Number of subjects: 7
Study 11315837 — intervention group
Group type: COMPARATOR
Intervention: GLP-1
Number of subjects: 7
Study 9006356 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 168
Study 9006356 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbogen inhalation therapy
Number of subjects: 168
Study 8390514 — intervention group
Group type: EXPERIMENTAL
Intervention: E + Stroop (60 min exercise at 60% maximal oxygen uptake followed by Stroop color word task)
Number of subjects: 8
Study 8390514 — intervention group
Group type: COMPARATOR
Intervention: Stroop (Stroop color word task without prior exercise)
Number of subjects: 8
Study 8390514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex (60 min exercise at 60% maximal oxygen uptake followed by 20 min seated recovery)
Number of subjects: 8
Study 3684738 — intervention group
Group type: EXPERIMENTAL
Intervention: 150-watt xenon-arc solar simulator
Number of subjects: 0
Study 3684738 — intervention group
Group type: COMPARATOR
Intervention: 300-watt Osram Ultravitalux bulbs
Number of subjects: 0
Study 11323042 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for 70-99% stenosis
Number of subjects: 216
Study 11323042 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for 50-69% stenosis
Number of subjects: 216
Study 11323042 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for 65-74 years
Number of subjects: 216
Study 11323042 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy for less than 65 years
Number of subjects: 216
Study 11323042 — intervention group
Group type: COMPARATOR
Intervention: Perioperative risk of stroke and death
Number of subjects: 216
Study 11323042 — intervention group
Group type: EXPERIMENTAL
Intervention: Number needed to treat
Number of subjects: 216
Study 30540556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheo Knee XC
Number of subjects: 6
Study 30540556 — intervention group
Group type: COMPARATOR
Intervention: C-Leg
Number of subjects: 6
Study 30285042 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 L of water daily (water group)
Number of subjects: 140
Study 30285042 — intervention group
Group type: COMPARATOR
Intervention: No additional fluids (control group)
Number of subjects: 140
Study 27137175 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity aerobic exercise (45' at 50% of maximum heart rate)
Number of subjects: 20
Study 27137175 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise (45' at 75% of maximum heart rate)
Number of subjects: 20
Study 27137175 — intervention group
Group type: COMPARATOR
Intervention: Control (45' of rest)
Number of subjects: 20
Study 25275613 — intervention group
Group type: EXPERIMENTAL
Intervention: First analgesic treatment with positive or negative experiences (details on dosage and duration not provided)
Number of subjects: 0
Study 25275613 — intervention group
Group type: EXPERIMENTAL
Intervention: Second different analgesic treatment (details on dosage and duration not provided)
Number of subjects: 0
Study 25275613 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological trait variables (anxiety, depression, locus of control)
Number of subjects: 0
Study 25275613 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging data
Number of subjects: 0
Study 21877951 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg of dried rosemary leaf powder
Number of subjects: 28
Study 21877951 — intervention group
Group type: EXPERIMENTAL
Intervention: 6,000 mg of dried rosemary leaf powder
Number of subjects: 28
Study 21877951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21203437 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV + VAX102
Number of subjects: 80
Study 21203437 — intervention group
Group type: COMPARATOR
Intervention: TIV + placebo
Number of subjects: 80
Study 17083342 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine
Number of subjects: 375
Study 17083342 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus cyclophosphamide (FC)
Number of subjects: 375
Study 15034215 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed 3 mg/m2 iv on day 1 and oxaliplatin 70 mg/m2 iv on day 1 and day 8 every 3 weeks
Number of subjects: 44
Study 15034215 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed plus oxaliplatin regimen
Number of subjects: 44
Study 15034215 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of the treatment
Number of subjects: 44
Study 12466015 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Sodium Treatment (LS: 143 10 mM)
Number of subjects: 10
Study 12466015 — intervention group
Group type: EXPERIMENTAL
Intervention: High Sodium Treatment (HS: 434+/‐17 mM Na+/d excreted)
Number of subjects: 10
Study 12466015 — intervention group
Group type: COMPARATOR
Intervention: Head Down Bed Rest (HDBR)
Number of subjects: 10
Study 9660281 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. betamethasone
Number of subjects: 92
Study 9660281 — intervention group
Group type: COMPARATOR
Intervention: i.m. placebo
Number of subjects: 92
Study 9660281 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. betamethasone (in patients with positive culture for streptococcus species)
Number of subjects: 92
Study 7584191 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoothing with a xenon chloride excimer laser in grade II chondromalacia
Number of subjects: 0
Study 7584191 — intervention group
Group type: COMPARATOR
Intervention: Debridement and lavage
Number of subjects: 0
Study 2644051 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.04 mg.kg‐1 administered as a single bolus
Number of subjects: 14
Study 2644051 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.01 mg.kg‐1 followed by 0.03 mg.kg‐1 after 3 min (priming)
Number of subjects: 14
Study 2644051 — intervention group
Group type: COMPARATOR
Intervention: No priming (control)
Number of subjects: 14
Study 2644051 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with neostigmine
Number of subjects: 14
Study 31992344 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kHz spinal cord stimulation plus usual care
Number of subjects: 96
Study 31992344 — intervention group
Group type: COMPARATOR
Intervention: Sham 10 kHz spinal cord stimulation plus usual care
Number of subjects: 96
Study 28222548 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure body weight-supported treadmill training (BWSTT)
Number of subjects: 20
Study 28222548 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention overground walking assessments
Number of subjects: 20
Study 26160208 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC6A14 rs2312054 A allele carriers
Number of subjects: 344
Study 26160208 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC6A14 rs12391221 A allele carriers
Number of subjects: 344
Study 26160208 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC6A14 rs2071877 C allele carriers (boys)
Number of subjects: 344
Study 26160208 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTR2C rs3813928 A allele carriers
Number of subjects: 344
Study 26160208 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTR2C rs3813929 T allele carriers
Number of subjects: 344
Study 23253653 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational text messaging three times a day, 3 days a week, for 6 weeks
Number of subjects: 36
Study 23253653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messaging)
Number of subjects: 36
Study 23253653 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational text messaging
Number of subjects: 36
Study 21727148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 0
Study 21727148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 5.0 mg
Number of subjects: 0
Study 21727148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18165571 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil target-controlled infusion with randomized remifentanil targets ranging from 2 to 8 ng/mL, with half receiving neuromuscular blockade.
Number of subjects: 105
Study 16445497 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (density of melanocytes transplanted approximately 231.60+/‐ 27.03/mm(2))
Number of subjects: 20
Study 16445497 — intervention group
Group type: COMPARATOR
Intervention: Group B (density of melanocytes transplanted approximately 154.90+/‐ 27.65/mm(2))
Number of subjects: 20
Study 12628571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutout work surface
Number of subjects: 32
Study 12628571 — intervention group
Group type: COMPARATOR
Intervention: Regular work surface
Number of subjects: 32
Study 12628571 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined desktop
Number of subjects: 32
Study 12628571 — intervention group
Group type: COMPARATOR
Intervention: Horizontal desk
Number of subjects: 32
Study 10472223 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0 micrograms kg‐1
Number of subjects: 80
Study 10472223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram kg‐1
Number of subjects: 80
Study 10472223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms kg‐1
Number of subjects: 80
Study 10472223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 4 micrograms kg‐1
Number of subjects: 80
Study 8709688 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 1 g oral dose of ciprofloxacin
Number of subjects: 260
Study 8709688 — intervention group
Group type: COMPARATOR
Intervention: Single 300 mg oral dose of doxycycline
Number of subjects: 260
Study 8709688 — intervention group
Group type: COMPARATOR
Intervention: Single 300 mg oral dose of doxycycline (tetracycline-resistant strain)
Number of subjects: 260
Study 8709688 — intervention group
Group type: COMPARATOR
Intervention: Single 300 mg oral dose of doxycycline (tetracycline-susceptible strain)
Number of subjects: 260
Study 2018224 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of midazolam
Number of subjects: 16
Study 2018224 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study 2018224 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg)
Number of subjects: 16
Study 2018224 — intervention group
Group type: COMPARATOR
Intervention: No alcohol
Number of subjects: 16
Study 6750325 — intervention group
Group type: EXPERIMENTAL
Intervention: graded sequential mestranol and norethisterone
Number of subjects: 23
Study 6750325 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study 31775152 — intervention group
Group type: COMPARATOR
Intervention: 0 ppm F dentifrice/gel (H0/L0)
Number of subjects: 240
Study 31775152 — intervention group
Group type: COMPARATOR
Intervention: 1,450 ppm F dentifrice/gel (H1,450/L1,450)
Number of subjects: 240
Study 31775152 — intervention group
Group type: COMPARATOR
Intervention: 5,000 ppm F dentifrice/gel (H5,000/L5,000)
Number of subjects: 240
Study 31775152 — intervention group
Group type: COMPARATOR
Intervention: 12,500 ppm F dentifrice/gel (H12,500/L12,500)
Number of subjects: 240
Study 31775152 — intervention group
Group type: COMPARATOR
Intervention: 5,000 ppm F plus TCP dentifrice/gel (H5,000+TCP/L5,000+TCP)
Number of subjects: 240
Study 31441100 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAVE program (8-week supervised exercise training)
Number of subjects: 250
Study 31441100 — intervention group
Group type: COMPARATOR
Intervention: Usual care (wait list control)
Number of subjects: 250
Study 27566056 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple snare papillectomy (SSP)
Number of subjects: 50
Study 27566056 — intervention group
Group type: COMPARATOR
Intervention: Submucosal injection papillectomy (SIP)
Number of subjects: 50
Study 27132416 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue (single administration)
Number of subjects: 51
Study 27132416 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (single administration)
Number of subjects: 51
Study 27132416 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 51
Study 25117004 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation group
Number of subjects: 37
Study 25117004 — intervention group
Group type: COMPARATOR
Intervention: Sleep group
Number of subjects: 37
Study 25117004 — intervention group
Group type: COMPARATOR
Intervention: Day group
Number of subjects: 37
Study 22869471 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary spontaneous pneumothorax (PSP) group
Number of subjects: 234
Study 22869471 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteer group (no lung disease)
Number of subjects: 234
Study 22869471 — intervention group
Group type: EXPERIMENTAL
Intervention: PSP group
Number of subjects: 234
Study 22869471 — intervention group
Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 234
Study 19056607 — intervention group
Group type: EXPERIMENTAL
Intervention: Threonine intake ranging from 10 to 100 mg . kg(‐1) . d(‐1)
Number of subjects: 9
Study 17579202 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human luteinizing hormone (rhLH)
Number of subjects: 15
Study 17579202 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 15
Study 15531971 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐TSM
Number of subjects: 17
Study 15531971 — intervention group
Group type: COMPARATOR
Intervention: 3‐TTM
Number of subjects: 17
Study 11584913 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg cortisol
Number of subjects: 20
Study 11584913 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 20
Study 9444927 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical strategy involving biliary reconstruction after resection of extrahepatic bile ducts and gallbladder for PBM patients without CCD
Number of subjects: 0
Study 8181883 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitrate therapy (0.4 mg/h)
Number of subjects: 46
Study 3356109 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous aerosols with pH 2.6 and 10.0
Number of subjects: 21
Study 3356109 — intervention group
Group type: EXPERIMENTAL
Intervention: D-glucose solutions (osmolarity range 77-1232 mosmol/l)
Number of subjects: 21
Study 3356109 — intervention group
Group type: COMPARATOR
Intervention: Saline solutions (osmolarity range 77-1232 mosmol/l)
Number of subjects: 21
Study 3356109 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic and hypertonic mixtures of D-glucose and saline
Number of subjects: 21
Study 31443941 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (90% length screws with a fractured lateral hinge)
Number of subjects: 40
Study 31443941 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E (90% length screws with gap filling using a bone substitute)
Number of subjects: 40
Study 31443941 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (unicortically fixated: 55% of drilled tunnel length)
Number of subjects: 40
Study 31443941 — intervention group
Group type: COMPARATOR
Intervention: Group A (bicortically fixated)
Number of subjects: 40
Study 31443941 — intervention group
Group type: COMPARATOR
Intervention: Group B (unicortically fixated: 90% of drilled tunnel length)
Number of subjects: 40
Study 28429906 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutinous brown rice (GBR)
Number of subjects: 37